Optimal Dose https://validator.w3.org/feed/docs/rss2.html Sino Biopharmaceuticals CLDN18.2 ADC LM-302 granted Priority Review with China approval expected Weekly News 23 May to 29 May 2026 Weekly News 23 May to 29 May 2026 Adcendo and MSD partner to evaluate ADCE-T02 plus KEYTRUDA in phase 1b advanced Solid tumor study Gilead receives CHMP positive opinion for Trodelvy in 1L metastatic TNBC patients ineligible for PD-(L)1 inhibitors CHMP recommends EU approval of Enhertu for previously treated HER2-positive metastatic Solid tumours Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer Optimal Dose – CAR-T Digest (August 2020) Kelun-Biotech announces phase 3 trial of Sacituzumab Tirumotecan versus Chemotherapy as 1L treatment for advanced TNBC met primary endpoint of PFS Hengrui announces phase 3 trial of HER3 ADC SHR-A2009 for EGFR-mutant advanced NSCLC met primary endpoint of PFS Weekly News 16 May to 22 May 2026 Weekly News 16 May to 22 May 2026 TroFuse-005 trial evaluating Sacituzumab Tirumotecan met primary endpoints of OS and PFS in certain patients with advanced or recurrent Endometrial cancer PADCEV in combination with Keytruda receives positive CHMP opinion for the treatment of patients with resectable MIBC who are ineligible for cisplatin-based chemotherapy CDSCO approves Astellas’ PADCEV for first-line advanced Bladder cancer treatment ENHERTU approved in the US for two new indications for patients with HER2-positive early Breast cancer HS-20093 granted Breakthrough Therapy Designation by NMPA for Esophageal cancer treatment Weekly News 09 May to 15 May 2026 Weekly News 09 May to 15 May 2026 Astellas Pharma sNDA in Japan for PADCEV in combination with Keytruda for cisplatin-eligible patients with muscle-invasive Bladder cancer Emiltatug Ledadotin has been granted Breakthrough Therapy Designation by the U.S. FDA for the treatment of Adenoid cystic carcinoma Zai Lab announced that Zocilurtatug Pelitecan has received U.S. FDA FTD for the treatment of extrapulmonary Neuroendocrine carcinomas SYS6010 has received another BTD in China for the treatment of patients with locally advanced or metastatic ESCC The sNDA for Sacituzumab Tirumotecan in combination with Pembrolizumab as 1L treatment for PD-L1 positive NSCLC accepted for review by NMPA Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive metastatic breast cancer and 2L HER2-positive metastatic gastric cancer Weekly News 02 May to 08 May 2026 Weekly News 02 May to 08 May 2026 Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza ArriVent announces IND clearance for novel tetravalent MUC16/NaPi2b targeting ADC ARR-002 with initial focus in ovarian and endometrial cancers InnoCare Pharma’s independently developed CDH17-targeted ADC innovative drug ICP B208 has been approved for clinical trials HLX43 received PMDA acknowledgment to initiate a global Phase 2/3 trial in squamous non-small cell lung cancer MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study Innovent Biologics’ IBI343 met primary endpoint in phase 3 Gastric cancer trial with NDA accepted by NMPA Weekly News 30 May to 05 June 2026 Weekly News 30 May to 05 June 2026 Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358 SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma Monthly Digest – June 2026 Monthly Digest – June 2026 Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic SYS6051 obtains clinical trial approval in the U.S. Weekly News 25 April to 01 May 2026 Weekly News 25 April to 01 May 2026 Novartis withdraws EMA application for adding new indication for Pluvicto Taiho Pharmaceutical and Araris Biotech AG advance ADC ARC-02 into phase 1 clinical development Alphamab Oncology announces IND application for TROP2/HER3 bispecific ADC JSKN016SC officially accepted by CDE